Note: This analysis is not an endorsement of any political figure or party. It provides an impartial evaluation of policy impacts from the first Trump administration on the lab testing industry, specifically focusing on how such policies could influence Physician Office Labs (POL) and related sectors.
The big idea: Physician Office Labs (POLs) are critical in enhancing clinical decision-making and patient care across the U.S. healthcare landscape. With the potential for policy shifts under a second Trump administration, small medical practices might find more opportunities to develop in-house lab testing capabilities. Here’s what that could look like.
Regulatory Relief for Small Medical Practices & Labs
President Trump’s first administration prioritized reducing regulations, which helped small businesses—including healthcare providers—operate more freely.
Why it matters: Fewer regulations can lead to lower operational costs for POLs, enabling more practices to establish and sustain lab testing.
By the numbers: Trump’s administration reported a 2:1 ratio of deregulated policies to new regulations, creating potential cost savings for healthcare providers.
Tax Cuts and Financial Incentives for Healthcare Providers
The Tax Cuts and Jobs Act of 2017 lowered tax rates across the board, giving healthcare providers more financial flexibility to invest in lab infrastructure.
Why it matters: With lower tax rates, medical practices have more capital for in-house lab capabilities, improving patient care options.
By the numbers: Corporate tax rates fell from 35% to 21%, with small businesses seeing average tax cuts between 10-20%.
Boosting Domestic Manufacturing & Medical Supply Chains
“Buy American, Hire American” policies aimed to encourage domestic production, including medical supplies.
Why it matters: A stronger domestic supply chain means more stability and potentially lower costs for essential lab supplies, crucial for POL sustainability.
By the numbers: Domestic production of medical equipment increased by about 4.5% from 2017 to 2020.
Expanding Healthcare Savings Accounts (HSAs) & Patient Flexibility
President Trump promoted expanding HSAs, which provide patients with more spending flexibility, including for lab tests.
Why it matters: With increased HSA contributions, patients are better positioned to demand lab testing as part of their personalized care.
By the numbers: HSA contributions rose 18% in 2019, with similar growth expected if contribution limits are expanded.
Focus on Deregulation of Medicare & Medicaid Requirements
President Trump’s administration sought to reduce federal oversight in Medicare and Medicaid, impacting lab reimbursements.
Why it matters: Simplified requirements could allow labs billing Medicare to optimize reimbursements, enhancing profitability.
By the numbers: Labs billing Medicare saw an estimated 3% increase in reimbursements due to deregulatory measures.
Deprioritization of LDT Regulation
Laboratory-developed tests (LDTs) face a regulatory crossroads. A Trump administration could deprioritize enforcement, influencing innovation and compliance burdens for labs.
Judicial Action: Trump-appointed Judge Jordan may issue a summary judgment siding with ACLA/AMP in their lawsuits against the FDA’s LDT rule. If this happens, Trump’s FDA is unlikely to appeal the decision, halting enforcement of the rule.
Congressional Influence: A Republican-controlled Congress, with bipartisan interest in revisiting LDT oversight (e.g., VALID Act), could pass new “lab-friendly” legislation to replace the FDA’s rule.
Administrative Focus: Trump’s FDA might shift focus to food safety and drug pricing rather than prioritizing LDT regulation.
By the numbers: The stage 1 compliance deadline for FDA’s LDT final rule remains May 6, 2025.
The bottom line: A second Trump administration may bring advantages for Physician Office Labs by reducing regulatory barriers, increasing available capital, and strengthening the medical supply chain. For POLs, this could mean lower costs, greater stability, and increased investment in in-house lab testing—all of which drive better patient outcomes and clinical decision-making.
Comments